7[1]Livermore DM .Determinants of the activity of β- lactamase inhibitor combinations[J] .J Antimicrob Chemother, 1993, 31(suppl): 9. 被引量：1
8[2]Payne DJ ,Cramp R,Winstanley DJ,et al .Comparative activities of clavulanic acid, sulbactam,and tazobactam against clinically important β - lactamases[J] .Antimicrob Agents Chemother, 1994,38: 767. 被引量：1
5Yoneyama H, Katsumata R. Antibiotic resistance in bacteria and its future for novel antibiotic development[J]. Biotechnol Biochem, 2006,70(5) :1060- 1075. 被引量：1
6Van-Bambeke F,Tulkens P M. Macrolides: pharmacokinetics and pharmacodynamics [ J ]. Int J Antimicrob Agents, 2001,18 ( Suppl 1) :S17. 被引量：1
7Zorov S D, Iuzenkov Iu V, Severinov K V. Low- molecular weight inhibitors of bacterial DNA-dependent RNA polymerase[J]. Mol Biol(Mosk) ,2006,40(6) :971-981. 被引量：1
8Perilli M,Segatore B,Tavio M,et al. In xitro selection and characterization of mutants in TEM-- 1 -- producing, Escherichia coli by Ceftaziolime and Ceftibuten[J]. J Chemother, 2007,19 (2): 123 - 126. 被引量：1
9Fluit A C, Visser M R, Schmitz F J. Molecular detection of antinicrobial resistance [J]. Clin Microbiol Rev, 2001,14 : 836- 871. 被引量：1
10Sunakawa K. Appropriate use of anti-MRSA drugs[J]. Jpn J Antibiot,2007,60(1) :1-16. 被引量：1
